BioCardia (BCDA) just unveiled an announcement.
BioCardia, Inc. has kicked off patient enrollment for its critical Phase III CardiAMP Cell Therapy trial, targeting the treatment of chronic ischemic heart failure with reduced ejection fraction. This step marks a significant milestone as the company advances towards potentially offering new hope for patients suffering from this debilitating condition.
See more data about BCDA stock on TipRanks’ Stock Analysis page.
